Cover Image
市場調查報告書

自動及快速微生物檢測全球市場

Automated and Rapid Microbiological Tests

出版商 Global Industry Analysts, Inc. 商品編碼 225190
出版日期 內容資訊 英文 451 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
自動及快速微生物檢測全球市場 Automated and Rapid Microbiological Tests
出版日期: 2017年01月01日 內容資訊: 英文 451 Pages
簡介

本報告調查全球自動及快速微生物檢測市場,彙整市場及產品概要、最新產業趨勢與各種影響市場成長因素分析、產品和技術種類及概要、自動及快速檢測導入領域及應用、企業產品創新及發售等趨勢、企業與企業間動態、主要企業簡介、全球主要地區和各國市場趨勢,以及市場規模推移預測等情報。

第1部 前言、研究方法、產品定義

第2部 摘要整理

第1章 產業概要

  • 全球IVD市場
  • 中央實驗室:市場中心
  • 免疫化學:主要部門
  • 自動及快速微生物檢測:微生物檢測創新
  • 微生物進化的戰鬥:推動未來市場
  • 病原體即時檢測
  • 傳統快速微生物檢測:讓道給新探頭試驗
  • 新興市場:提供龐大成長機會
  • 臨床應用
  • 非臨床應用、其他

第2章 競爭環境

  • 競爭動力學:困難梭狀芽孢桿菌檢測市場
  • 困難梭狀芽孢桿菌檢測產品列表

第3章 市場成長推動因素、各種趨勢

  • 感染症罹患率增加:市場機會
  • 因老年人口而不斷增加的醫療需求:成長推動因素
  • 全球人口老化
  • HIV盛行率上升:主要市場機會
  • HIV統計:按地區
  • 快速HIV檢測:新時代診斷方法
  • 超快速HIV篩選檢查
  • 家用HIV檢測準確度/可靠性
  • 新興市場醫療支出擴大
  • 對實驗室自動化的投注提升:貢獻市場成長
  • 患者認知度提升:推動成長
  • 分子診斷的進步
  • 抗生速抗藥性細菌
  • 流行性感冒:推動快速檢測展望
  • FDA核准的主要流感A&B快速測試檢測
  • 自動血液培養系統、其他

第4章 主要課題

  • 驗證:必須要件
  • 獲得監管核准:主要非技術相關阻礙
  • 測試要件的非適合性
  • 技術和成本課題:導入食品部門的阻礙

第5章 產品、技術概要

  • 自動及快速微生物檢測:定義
  • 快速檢測的運作
  • 實現技術
  • 基於成長的技術
  • 基於生存力的技術
  • 細胞成分或人造基礎的技術
  • 基因組/蛋白質組
  • 微陣列/微流體
  • DNA微晶片/探頭
  • PCR
  • 免疫測定
  • NAT、其他

第6章 自動及快速微生物檢測應用領域:概述

  • 臨床應用
  • 自動識別和易感性檢測系統
  • 自動血液培養系統
  • 自動結核系統
  • 鏈球菌感染快速檢測
  • GC/披衣菌快速檢測
  • 其他自動及快速微生物檢測
  • 非臨床部門各種應用
  • 食品、水的安全性
  • 醫藥品部門
  • 環境檢測
  • 其他、等

第7章 產品創新和發售

  • bioMerieux:推出DNA□RNA萃取新平台
  • Bio-Rad:推出IH-1000血型判定系統
  • bioMerieux:推出"EviSight™ Compact"孵養器系統
  • BD:推出次世代自動ID/AST系統、其他

第8章 近年產業動向

  • Abbott:申請取消與Alere的收購協議
  • Hologic:Aptima® 以HSV化驗通過CE標誌核准
  • Hologic:Aptima® 通過加拿大保健單位核准
  • Quidel:以鏈球菌菌株Solana® 化驗通過FDA核准
  • Quidel:以A□B型流感Solana® 化驗通過FDA核准
  • BD:以BD MAX™ CT/GC/TV化驗通過FDA核准、其他

第9章 全球主要企業

  • Abbott Laboratories (美國)
  • Abbott Molecular, Inc. (美國)
  • Alere Inc. (美國)
  • Beckman Coulter, Inc. (美國)
  • Becton Dickinson and Company (美國)
  • bioMerieux SA (法國)
  • bioMerieux, Inc. (美國)
  • Bio-Rad Laboratories, Inc (美國)
  • Cellabs Pty Ltd (澳洲)
  • Cepheid Inc. (美國)
  • CorisBioconcept SPRL (比利時)
  • F. Hoffmann-La Roche AG (瑞士)
  • Hologic, Inc. (美國)
  • MedMira Inc. (加拿大)
  • Meridian Bioscience, Inc. (美國)
  • OraSure Technologies, Inc. (美國)
  • Orion Diagnostica Oy (芬蘭)
  • QIAGEN N.V. (The 荷蘭)
  • Quidel Corporation (美國)
  • Sekisui Diagnostics, LLC (美國)
  • Siemens Healthcare GmbH (德國)
  • Thermo Fisher Scientific Inc. (美國)
  • Oxoid Limited (英國)

第10章 全球市場展望

第3部 市場分析

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 西班牙
    • 俄國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 其他
  • 拉丁美洲
    • 巴西
    • 其他
  • 其他

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-1093

This report analyzes the worldwide markets for Automated and Rapid Microbiological Tests in US$ Thousand by the following End-Use Segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, & Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 83 companies including many key and niche players such as -

Abbott Laboratories
Alere Inc.
Beckman Coulter, Inc.
Becton Dickinson and Company
bioMerieux SA

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Clinical Applications
      • Automated Identification and Susceptibility Systems
      • Automated Blood Culture Systems
      • Automated Tuberculosis Systems
      • Streptococcal Infection Rapid Tests
      • GC/Chlamydia Rapid Tests
      • Other Automated & Rapid Microbiological Tests
    • Non-Clinical Applications

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Global In-Vitro Diagnostics Market
    • Table 1: Global In-Vitro Diagnostics (IVD) Market by Geographic Region (2015): Percentage Share Breakdown of Revenues for the US, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World (includes corresponding Graph/Chart)
  • Central Laboratories Dominate the Market
    • Table 2: Global In-Vitro Diagnostics Market by Sector (2015): Percentage Breakdown of Revenues for Hospital & Central Laboratories, Decentralized & Patient Self-Testing (includes corresponding Graph/Chart)
  • Immunochemistry - the Leading Segment
    • Table 3: Global In-Vitro Diagnostics Market by Segment (2015): Percentage Breakdown of Value Sales for Immunochemistry, Self-Monitoring Blood Glucose, Point-of-Care Diagnostics, Molecular Diagnostics, Tissue Diagnostics, Hematology, Microbiology, and Others (includes corresponding Graph/Chart)
    • Table 4: Global In-Vitro Diagnostics Market by Leading Player (2015): Percentage Share Breakdown of Revenues for Roche, Siemens, Abbott, Danaher, Thermo Fisher Scientific, Becton Dickinson, Alere, Sysmex, bioMerieux, Ortho Clinical Diagnostics, and Others (includes corresponding Graph/Chart)
  • Automated and Rapid Microbiological Tests Revolutionize Microbiological Testing
  • Evolutionary Battle against Microbes Drives Market Future
  • Automated Microbiological Tests: A Pesky Gray Area in the Clinical Diagnostics Market
  • Instant Detection of Pathogens - A New Epoch in the Fight for Survival
  • Traditional Rapid Microbiological Tests Make Way for New, Probe Tests
  • Emerging Markets Provide Tremendous Growth Opportunities
  • Clinical Applications
    • Table 5: Global Automated and Rapid Microbiological Tests Market in Clinical Applications by Region: (2016) (includes corresponding Graph/Chart)
    • Table 6: Global Automated and Rapid Microbiological Tests Market in Clinical Applications by Segment: (2016) (includes corresponding Graph/Chart)
  • Non-Clinical Applications
    • Table 7: Global Automated and Rapid Microbiological Tests Market in Non-Clinical Applications by Region: (2016) (includes corresponding Graph/Chart)
  • A Holistic Peek into a Few Noteworthy Trends
  • The Evolution of Biotechnology - A Crucial Step Ahead in the Growing Popularity of Rapid Microbial Tests
  • Point-of-Care Rapid Microbiological Testing: Yet to Realize Its Full Potential...

2. COMPETITION

    • Table 8: Global Microorganism Identification and Resistance Tests Market by Leading Player (2015): Percentage Market Share Breakdown of Value Sales for bioMerieux, Becton Dickinson, Thermo Fisher, Beckman Coulter, Others (includes corresponding Graph/Chart)
    • Table 9: Global Blood Screening Market by Leading Player (2015): Percentage Market Share Breakdown of Value Sales for Hologic, Roche and Others (includes corresponding Graph/Chart)
    • Table 10: Global GC-CT Testing Market by Leading Player (2015): Percentage Market Share Breakdown of Value Sales for Hologic, Becton Dickinson, Roche, Qiagen NV, and Others (includes corresponding Graph/Chart)
  • Competitive Dynamics in the C. Difficile Testing Market
    • Table 11: Global Molecular Diagnostics Market for Clostridium difficile by Leading Player (2015): Percentage Breakdown of Revenues for Cepheid, Meridian, Becton Dickinson, and Others (includes corresponding Graph/Chart)
  • List of Select Molecular C. difficile Test Products

3. MARKET DRIVERS AND TRENDS

  • Increasing Incidence of Infectious Diseases - An Opportunity Indicator
  • Rising Healthcare Needs of Aging Global Population - A Growth Driver
    • Table 12: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)
    • Table 13: Global Population Statistics for 65+ Age Group (2014) (includes corresponding Graph/Chart)
    • Table 14: Aged Population (65+ Years) as a Percentage of the Total Population by Region: 2000 Vis-a-vis 2025 (includes corresponding Graph/Chart)
  • The World is Ageing
    • Table 15: Elderly Population (65+ Years) as a Percentage of the Total Population: 2014 & 2025 (includes corresponding Graph/Chart)
  • Rising HIV Prevalence - A Key Opportunity Indicator
  • Some Significant HIV Statistics by Region: 2015
    • Table 16: Global Prevalence of HIV Infection in 2015 by Region (in Millions) (includes corresponding Graph/Chart)
    • Table 17: Newly Infected HIV Population in 2015 by Region (in Thousands) (includes corresponding Graph/Chart)
    • Table 18: Global HIV Related Deaths in 2015 by Region (in Thousands) (includes corresponding Graph/Chart)
  • Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer Disease
  • Ultra-Rapid HIV-Screening Tests put up a Strong Fight against HIV-Epidemic
  • Accuracy/Reliability of Home HIV Testing: A Bone of Contention
  • Increase in Healthcare Spending in Emerging Markets to Propel Demand
    • Table 19: Healthcare Spending as % of GDP by Region (2016E) (includes corresponding Graph/Chart)
    • Table 20: Healthcare Spending as % of GDP in Select Countries (2014) (includes corresponding Graph/Chart)
  • Rising Emphasis on Lab Automation to Augur Well for Market Growth
  • Greater Patient Awareness to Drive Growth
  • Advancements in Molecular Diagnostics - A Boon
  • Antibiotic Resistant Bacteria Throws the Spotlight on Microbial Testing
  • Influenza - Boosting Rapid Test Prospects
  • Select FDA-approved Rapid Detection Tests for Flu A&B: (2015)
  • Automated Blood Culture Systems: The Gold Standard in the Fight against Bacteremia
  • Impact of Food Scares on Rapid Microbiological Tests Market
  • Stringent Norms Necessitate Microbial Food Safety Testing
  • Rapid Screening Gains Preference over Traditional Food Testing Procedures
  • Conventional Testing Continues to Dominate but Rapid Tests Making Inroads
  • Leading Food Processors Resort to Rapid Microbiological Testing
  • Food Packages of the Future Ingrained with Microbial Alert Systems
  • Poultry Industry Embraces Rapid Microbiological Testing Technologies
  • Rapid Microbiological Tests Gain Significance in the Pharma Industry
  • Key Advantages of Rapid Microbiological Tests for Pharma- In a Nutshell
  • Growth Direct(tm) System Creates Waves in Pharmaceutical Quality Control

4. KEY ISSUES CONFRONTING THE RAPID MICROBIOLOGICAL TESTS MARKET

  • Validation: An Imperative Prerequisite
  • Obtaining Regulatory Approval: A Major Non-Technical Hindrance
  • Non-Conformance to Testing Requirements: A Weighty Concern
  • Technical and Cost Issues Impede the Uptake of Rapid Microbiological Tests in the Food Sector

5. PRODUCT/TECHNOLOGY OVERVIEW

  • Automated & Rapid Microbiological Tests: A Definition
  • How Does a Rapid Test Work?
  • Enabling Technologies of Automated & Rapid Microbiological Tests
  • Growth-based Technologies
  • Viability-based Technologies
  • Cellular-Component or Artifact-based Technologies
  • Genomics/Proteomics
  • Microarrays/Microfluidics
  • DNA Microchips/Probes
  • Polymerase Chain Reaction (PCR)
  • Immunoassay
  • Nucleic Acid Testing (NAT)
    • Nucleic Acid Probes
    • Signal-Amplified Tests
    • Nucleic Acid Amplification Tests
  • Traditional Methods with Computer-Aided Imaging
  • Combination Methods

6. APPLICATION AREAS OF AUTOMATED AND RAPID MICROBIOLOGICAL TESTS - A REVIEW

  • Clinical Applications
  • Automated Identification and Susceptibility Systems
  • Automated Blood Culture Systems
  • Automated Tuberculosis Systems
  • Streptococcus Infection Rapid Tests
    • Streptococcus A Rapid Tests
    • Streptococcus B Rapid Tests
  • GC/Chlamydia Rapid Tests
  • Other Automated & Rapid Microbiological Tests
    • Respiratory Rapid Tests
      • RSV/ Influenza Rapid Tests
    • Gastrointestinal Rapid Tests
      • Giardia Lamblia Rapid Tests
      • H. Pylori Rapid Tests
      • Cryptosporidium Rapid Tests
      • C. Difficile Rapid Tests
    • STD Rapid Tests
      • HIV Rapid Tests
      • Advantages of Rapid HIV Testing
      • Disadvantages of Rapid HIV Testing
      • Syphilis Rapid Tests
  • Applications in Non-Clinical Investigations
  • Food/Water Safety Tests
    • Food Safety Testing: A Lucrative Application Area
    • qPCR Application in Food Microbiology: Study of Select Micro-Organisms by Target Gene and Food Substrate
  • Rapid Microbiological Methods in Pharmaceutical Sector
    • Limitations
    • Advantages
    • Applications in Pharmaceutical Sector
  • Environmental Tests
  • Other Miscellaneous Applications

7. PRODUCT INNOVATIONS/INTRODUCTIONS

  • bioMerieux Launches New Platform for Extraction of DNA and RNA
  • Bio-Rad Launches IH-1000 Blood Typing System
  • bioMerieux Launches "EviSight(tm) Compact" Incubator System
  • BD Launches Next Generation Automated ID/AST System
  • Sekisui Introduces SEKURE(r) TPLA and RPR Assays for Syphilis Testing
  • BD Introduces BD Veritor(tm) Plus System
  • Rhoenix Introduces Beer SpoilerAlert(tm) Assay
  • Philips Introduces Minicare I-20 System
  • Bio-Rad Introduces Amplichek(tm) II Quality Control
  • Bruker Launches Enhancements for MALDI Biotyper
  • Thermo Fisher Launches Thermo Scientific SureTect Cronobacter Species Real-Time PCR Assay
  • Hologic Introduces Aptima Mycoplasma Genitalium Assay
  • bioMerieux and Illumina Introduce bioMerieux EpiSeq(tm)
  • bioMerieux Launches GENE-UP(r)
  • BioControl Launches Modular Automation for Assurance GDS(r)
  • Rapid Micro Biosystems Launches Growth Direct(tm) System
  • IDEXX Launches Quanti-Tray Sealer PLUS in Europe
  • Sekisui Introduces 3 New Assays to the OSOM Rapid Test Line
  • Bio-Rad Launches IH-500
  • bioMerieux Launches VIDAS(r) Lyme IgG II and VIDAS(r) Lyme IgM II Assays in the US
  • Meridian Introduces illumigene(r) HSV Assays in Europe
  • Medicinal Genomics Introduces PathogINDICAtor(tm) Assay
  • Roche Introduces cobas(r) DPX Test

8. RECENT INDUSTRY ACTIVITY

  • Abbott Files for Cancellation of Acquisition Agreement with Alere
  • Hologic Obtains CE Mark Approval for Aptima(r) HSV Assay
  • Hologic Obtains Health Canada Approval for Aptima(r) Hepatitis C and B Quant Assays
  • Quidel Obtains FDA Approval for Solana(r) Assay for Various Streptococcus Strains
  • Quidel Obtains FDA Approval for Solana(r) Assay for Influenza A&B
  • BD Receives FDA Approval for BD MAX(tm) CT/GC/TV Assay
  • OraSure Obtains BARDA Funding for Zika Tests
  • Alere Obtains FDA Approval for Alere(tm) i RSV Rapid Molecular Test
  • Magellan Diagnostics Obtains Chinese Approval for LeadCare(r) II
  • Alere Receives CE Mark for Alere(tm) Reader
  • Sekisui Secures Distribution Rights for FastPack(r) IP System from Qualigen
  • bioMerieux Submits 510(k) Application for BacT/ALERT(r) VIRTUO(tm)
  • Alere Begins Operations at New Facility in India
  • Alere Obtains WHO Prequalification for Alere(tm) HIV Combo
  • Hologic and Grifols Receive FDA Approval for Procleix Zika Virus Assay
  • Meridian Obtains FDA Approval for illumigene(r) Mycoplasma Direct Assay
  • Alere Announces WHO Prequalification for Alere(tm) q HIV-1/2 Detect Assay
  • BD and Check-Points Enter into Development and Distribution Agreement
  • Luminex to Acquire Nanosphere
  • bioMerieux Takes Over Hyglos
  • BD Receives CE Mark for BD MAX(tm) Vaginal Panel
  • Siemens Healthcare Changes Name to Siemens Healthineers
  • Sekisui and Qualigen Enter into Partnership
  • Meridian Obtains CE Mark for illumigene(r) Mycoplasma Direct
  • BioFire Obtains FDA and CE Mark Approval for FilmArray(r) Torch use with all FilmArray(r) Panels
  • Roche Receives FDA IND Approval for cobas(r) Zika Assay
  • Meridian Takes Over Magellan Biosciences
  • Thermo Fisher Obtains FDA Approval for B*R*A*H*M*S PCT Assay for Sepsis Risk Assessment
  • BioFire Obtains FDA Approval for FilmArray(r) Torch for use with FilmArray(r) Respiratory Panel
  • Abbott Signs Acquisition Agreement with Alere
  • Siemens Receives FDA Approval for Sysmex(r) CS-2100i System
  • Bio-Rad Receives FDA Approval for TANGO infinity(r) system
  • Bio-Rad Obtains FDA Approval for D-100(tm) System for A1c Testing
  • MedMira Obtains FDA Approval for Reveal(r) G4 Rapid HIV-1 Antibody Test
  • FDA Approves cobas(r) HBV and cobas(r) HCV Viral Load Tests for cobas(r) 6800 and cobas(r) 8800 Systems
  • Hologic Obtains CE-IVD Certification for Aptima(r) HCV Quant Dx Assay on Panther(r) System
  • BD and Seegene Enter into Collaboration Agreement
  • FDA Emergency Authorization for OraSure OraQuick(r) Ebola Rapid Antigen Test
  • Bio-Rad Obtains Pre-Market Approval for BioPlex 2200 HIV Ag-Ab Assay
  • FDA Approves VIDAS(r) 3 Immunoassay from bioMerieux
  • Meridian Obtains FDA Approval for illumigene(r) HSV 1&2
  • Charles River Laboratories Acquires Celsis International
  • FDA Approves Quidel Solana(tm) Molecular System and Solana(tm) Molecular Assay
  • FDA Approves Roche cobas HSV 1 and 2 Test
  • FDA Approves Roche cobas Cdiff Test
  • MedMira Submits Supplement for FDA Approval of Reveal(r) G4 Rapid HIV-1 Antibody Test
  • FDA Approves Alere(tm) i Strep A Rapid Molecular Test
  • bioMerieux Acquires CREERAM Tools
  • FDA Gives CLIA Waiver Alere(tm) i Influenza A & B Test
  • Alere Obtains CE Mark Approval for Alere(tm) HIV Combo
  • Alere Obtains IVD CE Mark Approval for Alere(tm) q HIV-1/2 Detect Assay for Molecular Diagnosis of HIV at the Point of Care
  • FDA Gives CLIA Waiver for Alere(tm) i Strep A Rapid Molecular Test
  • BioFire Obtains FDA Approval and CE-IVD Marking for FilmArray(r) 2.0 System
  • FDA Approves Next Generation cobas MRSA/SA Test of Roche
  • FDA Approves cobas(r) TaqScreen MPX Test, v2.0 of Roche
  • bioMerieux Signs Strategic Agreement with COPAN

9. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott Laboratories (US)
  • Abbott Molecular, Inc. (US)
  • Alere Inc. (US)
  • Beckman Coulter, Inc. (US)
  • Becton Dickinson and Company (US)
  • bioMerieux SA (France)
  • bioMerieux, Inc. (US)
  • Bio-Rad Laboratories, Inc (US)
  • Cellabs Pty Ltd (Australia)
  • Cepheid Inc. (US)
  • CorisBioconcept SPRL (Belgium)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Hologic, Inc. (US)
  • MedMira Inc. (Canada)
  • Meridian Bioscience, Inc. (US)
  • OraSure Technologies, Inc. (US)
  • Orion Diagnostica Oy (Finland)
  • QIAGEN N.V. (The Netherlands)
  • Quidel Corporation (US)
  • Sekisui Diagnostics, LLC (US)
  • Siemens Healthcare GmbH (Germany)
  • Thermo Fisher Scientific Inc. (US)
  • Oxoid Limited (UK)

10. GLOBAL MARKET PERSPECTIVE

    • Table 21: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 22: World Historic Review for Automated and Rapid Microbiological Tests by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 23: World 14-Year Perspective for Automated and Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 24: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 25: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 26: World 14-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 27: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 28: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 29: World 14-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Segment - Percentage Breakdown of Dollar Sales for Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 30: World Recent Past, Current & Future Analysis for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 31: World Historic Review for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 32: World 14-Year Perspective for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 33: World Recent Past, Current & Future Analysis for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 34: World Historic Review for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 35: World 14-Year Perspective for Automated Blood Culture Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 36: World Recent Past, Current & Future Analysis for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 37: World Historic Review for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 38: World 14-Year Perspective for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 39: World Recent Past, Current & Future Analysis for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 40: World Historic Review for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 41: World 14-Year Perspective for Streptococcal Infection Rapid Testsin Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 42: World Recent Past, Current & Future Analysis for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 43: World Historic Review for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 44: World 14-Year Perspective for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 45: World Recent Past, Current & Future Analysis for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 46: World Historic Review for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 47: World 14-Year Perspective for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 48: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 49: World Historic Review for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 50: World 14-Year Perspective for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current & Future Analysis
      • Changing Healthcare Industry Dynamics Affect Rapid and Automated Microbiological Tests Market
    • Table 51: Healthcare Spending as a % of GDP (includes corresponding Graph/Chart)
    • Positive Outlook for Rapid and Automated Microbiological Tests Market
      • Rapidly Ageing Demographics Drive Growth
    • Table 52: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Competition
    • Tracking Trends Across Product Segments
      • Automated Identification & Susceptibility Systems
      • Growing Popularity of FDA-Approved Automated Susceptibility Testing Equipment
      • STD Rapid Tests
      • Market Shares of Leading Players
    • Table 53: The US Market for Syphilis Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Becton Dickinson, Alere, and Others (includes corresponding Graph/Chart)
      • Gastrointestinal Rapid Tests
    • Table 54: The US Market for Rotavirus Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Meridian Biosciences, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart)
      • Respiratory Rapid Tests
      • Competition
      • Market Share Data of Leading Players
    • Table 55: The US Market for Influenza Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Quidel, Becton Dickinson, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart)
    • Table 56: The US Market for RSV Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Becton Dickinson, Binax, Thermo Fisher Scientific and Others (includes corresponding Graph/Chart)
    • Table 57: The US Market for Mononucleosis Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Alere, Oxoid, Quidel and Others (includes corresponding Graph/Chart)
      • Streptococcus Infection Rapid Tests
    • Table 58: The US Market for Streptococcus A Rapid Tests by Leading Player (2015) - Percentage Breakdown of Value Sales for Quidel, Thermo Fisher Scientific, Becton Dickinson, and Others (includes corresponding Graph/Chart)
    • Testing Practices of the US Food Industry
    • Table 59: US Food Safety Testing Market by Contaminant (2015): Percentage Breakdown of Value Sales for Pathogens, GMOs, Toxins, Residues and Others (includes corresponding Graph/Chart)
    • Increasing Demand for Microbiology Tests in the Food Sector
    • Table 60: US Microbiological Food Safety Tests by Type (2015): Percentage Share Breakdown in terms of Number of Tests for Routine Tests and Pathogen Tests (includes corresponding Graph/Chart)
    • Tackling the Burden of Food Borne Illnesses
    • Table 61: Food-borne Illnesses, Hospitalizations and Deaths in the US (2011): Percentage Share Breakdown for Known Pathogens and Unspecified Agents (includes corresponding Graph/Chart)
    • Table 62: Leading Known Pathogens Causing Food-borne Illnesses in the US (2011): Percentage Share Breakdown of Number of Illnesses by Known Pathogens - Norovirus, Salmonella nontyphoidal, Clostridium perfringens, Campylobacter spp., Staphylococcus aureus, and Others (includes corresponding Graph/Chart)
    • Table 63: Leading Known Food-borne Pathogens Causing Hospitalizations in the US (2011): Percentage Share Breakdown of Number of Hospitalizations by Known Pathogens - Salmonella nontyphoidal, Norovirus, Campylobacter spp., Toxoplasma gondii, E. coli (STEC) O157, and Others (includes corresponding Graph/Chart)
    • Table 64: Leading Known Food-borne Pathogens Causing Deaths in the US (2011): Percentage Share Breakdown of Number of Deaths by Known Pathogens - Salmonella nontyphoidal, Norovirus, Campylobacter spp., Toxoplasma gondii, E. coli (STEC) O157, and Others (includes corresponding Graph/Chart)
    • Product Launches
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 65: The US Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 66: The US Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 67: The US 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current & Future Analysis
    • Food Safety Testing in Canada
    • Table 68: Canadian Food-Borne Illnesses by Category (2012): Percentage Share Breakdown of Number of Illness Caused through Known Pathogens and Unknown Pathogens (includes corresponding Graph/Chart)
    • Table 69: Canadian Food-Borne Illnesses by Pathogen (2012): Percentage Breakdown of number of Illness Caused by Norovirus, Clostridium perfringers, Campylobacter spp, Salmonella spp., non-typhoidal and Others (includes corresponding Graph/Chart)
    • Strategic Corporate Development
    • Medmira Inc. - A Key Player
  • B. Market Analytics
    • Table 70: Canadian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 71: Canadian Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 72: Canadian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current & Future Analysis
    • Demographics Drive Market Growth
    • Table 73: Japanese Population by Age Group (2012) (includes corresponding Graph/Chart)
    • Table 74: Japanese 65+ Years Population Share of Total Population: 1950-2015 (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 75: Japanese Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 76: Japanese Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 77: Japanese 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
      • Debt Crisis in Europe Affects Healthcare Industry
      • European Healthcare System: In a State of Transition
    • Ageing Demography - An Opportunity Indicator
    • Table 78: Population Breakup by Age Group for Select European Countries: 2015 (as Percentage of Total Population) (includes corresponding Graph/Chart)
    • Clinical Vis-a-vis Non-clinical Applications
    • What Drives the Requirement Patterns of End-Users?
    • Proliferation of Automated, and Rapid Tests in Clinical Applications
    • Non-Clinical Applications
    • Table 79: European Microbiological Food Safety Tests (2015): Percentage Share Breakdown of Number of Tests by Segment - Routine Tests and Pathogen Tests (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
    • Product Launches
  • B. Market Analytics
    • Table 80: European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia, & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 81: European Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia, & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014(includes corresponding Graph/Chart)
    • Table 82: European 14-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, & Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 83: European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 84: European Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 85: European 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current & Future Analysis
    • Product Launches
    • Strategic Corporate Developments
    • bioMerieux SA - A Key Player
  • B. Market Analytics
    • Table 86: French Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 87: French Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 88: French 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current & Future Analysis
    • Food Safety - A Cause of Concern
    • Food Safety Regulations in Germany
    • Strategic Corporate Developments
    • Siemens Healthcare GmbH - A Key Player
  • B. Market Analytics
    • Table 89: German Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 90: German Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 91: German 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 92: Italian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 93: Italian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated &Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 94: Italian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current & Future Analysis
      • Non-Clinical Applications to Exhibit Fastest Growth
    • Increasing Incidence of MRSA Spur Growth in Rapid Diagnostics
    • Oxoid Limited - A Key Player
  • B. Market Analytics
    • Table 95: The UK Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 96: The UK Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 97: The UK 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 98: Spanish Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 99: Spanish Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 100: Spanish 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4f. RUSSIA

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 101: Russian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 102: Russian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 103: Russian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Product Launches
    • Key Players
  • B. Market Analytics
    • Table 104: Rest of Europe Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 105: Rest of Europe Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 106: Rest of Europe 14-Year Perspective for Automated & Rapid Microbiological Tests by End-use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current & Future Analysis
      • Healthcare Spending in Asia-Pacific on the Rise
    • India & China Offer Significant Growth Opportunities
    • Table 107: China and India Lead Global Population (2013): Table Depicting China and India's Huge Population Vis-a-vis Other Countries' Population (in Million) by Age Group (includes corresponding Graph/Chart)
    • Table 108: Age-wise Breakup of China and India's Population Vis-a-vis Other Populous Countries Globally (2013) (includes corresponding Graph/Chart)
    • Asia-Pacific - The Next Epicenter for the AIDS Epidemic
  • B. Market Analytics
    • Table 109: Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 110: Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 111: Asia-Pacific 14-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 112: Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 113: Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 114: Asia-Pacific 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • IVD Market - An Overview
    • Table 115: Leading Players in the Chinese In-Vitro Diagnostics Market (2012): Percentage Breakdown of Value Sales for Abbott, Beckman/ Danaher, BioMerieux, DA AN, Hitachi, J&J, Mindray, Roche, Siemens, Sysmex and Others (includes corresponding Graph/Chart)
    • Current & Future Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 116: Chinese Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 117: Chinese Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 118: Chinese 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5b. INDIA

  • A. Market Analysis
    • Current & Future Analysis
    • Demand for Automated and Rapid Microbiology Testing Set to Grow in India
      • Growth Drivers
      • Automation - Name of the Game
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 119: Indian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 120: Indian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 121: Indian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Development
    • Cellabs Pty Ltd (Australia) - A Key Australian Player
  • B. Market Analytics
    • Table 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 123: Rest of Asia-Pacific Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 124: Rest of Asia-Pacific 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 125: Latin American Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 126: Latin American Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 127: Latin American 14-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)
    • Table 128: Latin American Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 129: Latin American Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 130: Latin American 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

6a. BRAZIL

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 131: Brazilian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/ Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 132: Brazilian Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 133: Brazilian 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

6b. REST OF LATIN AMERICA

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 134: Rest of Latin America Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 135: Rest of Latin America Historic Review for Automated & Rapid Microbiological Tests by End-Use Application- Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 136: Rest of Latin America 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Current & Future Analysis
  • B. Market Analytics
    • Table 137: Rest of World Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 138: Rest of World Historic Review for Automated & Rapid Microbiological Tests by End-Use Application - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 139: Rest of World 14-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Application - Percentage Breakdown of Dollar Sales for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top